

# BACKGROUND

Phospholipase C (PLC) enzymes, comprising several families (PLCbeta, gamma, delta, epsilon, eta, and zeta), have been established as crucial signaling molecules involved in regulation of a variety of cellular functions. PLC-catalvzed formation of the second messengers, inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol, from phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>), constitutes one of the major cell signaling responses. IP(3) induces a transient increase in intracellular free Ca<sup>2+</sup>, while DAG directly activates protein kinase C. These second messengers provide a common link from highly specific receptors for hormones, neurotransmitters, antigens, and growth factors to downstream, intracellular targets; thus, they contribute to regulation of biological functions as diverse as cell motility, fertilization, and sensory transduction.<sup>1</sup>

Of two PLCgamma enzymes, PLCgamma1 is ubiquitously expressed and appears to regulate a multitude of cellular functions in many tissues. It is activated in response to growth factor stimulation; in addition, its function in T-cell responses has been extensively documented. PLCgamma2, in contrast, is most highly expressed in cells of the hematopoietic system and plays a key role in regulation of the immune response. Both PLCgamma enzymes have also been implicated in signaling events underlying aberrant cellular responses. PLCgamma1 is critically involved in the regulation of cancer cell motility while PLCgamma2 has been implicated in deregulation of the immune responses resembling Btk-dependent X-linked agammaglobulinaemia and SLE disease in humans. It has been suggested that, in cancer cells, PLCgamma1 could function as a key, rate-limiting, common component involved in cell motility triggered by several growth factors and integrins.<sup>2</sup>

The domain organization of PLCgamma enzymes is characterized by the insertion of a highly structured region (PLCgamma-specific array, gammaSA) between the two halves of the TIMbarrel catalytic domain common to all PLCs. The gammaSA comprises a split PH (spPH) domain flanking two tandem SH2 domains and a SH3 domain. A distinct regulatory feature of PLCgamma enzymes is that their activation is linked to an increase in phosphorylation of specific tyrosine residues (most notably within the gammaSA) by receptor and non-receptor tyrosine kinases. Upon stimulation of cells with PDGF and EGF, the SH2 of PLC-gamma binds domain to the autophosphorylated tyrosine residues of growth factor receptors, leading to tyrosine phosphorylation and activation of PLC-gamma.<sup>3</sup> Full activation of PLC gamma 2 requires phosphorylation of Tyr753, 759, 1197, and 1217. All four tyrosines are phosphorylated following BCR engagement, most likely by Btk.<sup>4</sup> In addition, activation of PLC-gamma isozymes may occur secondarily to receptor-mediated activation of

phospholipase D and cytosolic phospholipase A<sub>2</sub>, which results in the production of phosphatidic acid and arachidonic acid, respectively.<sup>5</sup> It was also reported that PLC-gamma is regulated additionally by the lipid products of PI 3-kinase. The PH domain of PLC-gamma binds to PdtIns(3,4,5)P3, and is targeted to the membrane in response to growth factor stimulation and leads to activation of PI 3-kinase causes PLC-gamma PH domain-mediated membrane targeting and PLCgamma activation.<sup>6</sup> Furthermore, multiple proteinprotein interactions (mainly mediated by SH2 domains) also contribute to activation and have an important role in localizing PLCgamma into protein complexes with different binding partners, depending on cell type and specific cellular compartments. One mode of activation that is specific for the PLCgamma2 isozyme is direct binding to and activation by Rac. The interaction involves the spPH domain, and this activation mechanism does not require tyrosine phosphorylation.7

#### References:

- 1. Kim, M.G. et al: Exp. Mol. Med. 32:101-9, 2000
- 2. Patterson, R.L. et al: Trends in Biochem. Chem.
- 30:688-97, 2005 3. Nishibe, S. & Carpenter, G.: Semin Cancer Biol. 1:285-
- 92, 1990 4. Watanabe, D. et al: J. Biol. Chem. 276:38595-601,
- 2001
- 5. Sekiya, F. et al:Chem. Phys. Lipids 98:3-11, 1998
- 6. Falasca, M. et al: EMBO J. 17:414-22, 1998
- 7. Carpenter,G. & Ji, Q.: Exp. Cell Res. 253:15-24, 1999

## **TECHNICAL INFORMATION**

#### Source:

Phospho-PLC gamma 2 (Tyr1217) antibody is a rabbit antibody raised against a short peptide from human PLC gamma 2 sequence surrounding and containing phospho-Tyr1217.

#### Specificity and Sensitivity:

This antibody detects endogenous phosphorylated PLC gamma 2 (Tyr1217) proteins without cross-reactivity with other family members.

**Storage Buffer**: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

### Storage:

Store at -20°C for at least one year. Store at 4°C for frequent use. Avoid repeated freeze-thaw cycles.






### Phospho-PLC gamma 2 (Tyr1217) Antibody Cat. No. CG1467

Applications: Detected MW: Species & Reactivity: Isotype: WB, IHC, ELISA 147 kDa Human, Rat, Mouse Rabbit IgG

# **APPLICATIONS**

Application:	*Dilution:
WB	1:500-1:1000
IP	n/d
IHC	1:50-1:100
ICC	n/d
FACS	n/d
ELISA	1:1000

## **QUALITY CONTROL DATA**







 $\ensuremath{\text{Top:}}$  Western blot analysis of extracts from Jurkat cells treated with UV for 5 minutes.

**Middle:** Immunohistochemistry analysis of paraffinembedded Human brain gliomas (left) and Human liver carcinoma (right).

**Bottom:** ELISA for Immunogen Phosphopeptide (left) and Non-Phosphopeptide (right).

www.cellapplications.com 858-453-0848 800-645-0848 5820 Oberlin Dr. Suite 101 San Diego, CA 92121

